BLOOMINGTON, Ind. – Aamir Malik, an alumnus of the Indiana University Kelley School of Business, has been named executive vice president and chief business innovation officer of Pfizer Inc., a company known worldwide for its vaccines and for working to end the current COVID-19 pandemic.
Malik, who will be a member of Pfizer’s executive leadership team and report directly to the chairman and CEO, graduated from Kelley with a bachelor’s degree in finance in 1997 and today serves on the school’s Dean’s Council advisory board.
He comes to Pfizer after more than 24 years at McKinsey & Company, where he most recently served as the managing partner responsible for the firm’s U.S. operations. Previously, he led the firm’s global pharmaceuticals and medical products practice.
“We are living at a time of unprecedented scientific advancement, and Pfizer is a company that is unparalleled in its ambition to make a difference in patients’ lives,” Malik told the editor of biopharma news site Endpoints. “For me, there could be no professional opportunity greater than to leverage my diverse experiences across life-sciences to play a role in helping deliver on this aspiration, working alongside a leadership team for whom I have the deepest respect.”
Idalene “Idie” Kesner, dean of the Kelley School and the Frank P. Popoff Chair of Strategic Management, congratulated Malik and noted that his appointment reflects both Kelley’s traditional strengths in thought leadership in consulting and developing key decision makers in healthcare, the life sciences, and the pharmaceutical industry, especially at this time of unprecedented change.
“We’re proud of Aamir’s achievements. His path is just one example of how an innovative business education is valuable in many industries,” Kesner said. “His dedication also is testament to Kelley’s mission to be citizens of the world and to use our talents to affect positive change.”